Werewolf Therapeutics, Inc. (HOWL) | Investment Case

1. Company Snapshot

1.a. Company Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma.

The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies.Werewolf Therapeutics, Inc.was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on HOWL

Werewolf Therapeutics' recent performance was driven by several positive factors. The company's upgraded Zacks Rank to #2 (Buy) reflects growing optimism about its earnings prospects, which may drive the stock higher in the near term. Additionally, the appointment of Steven Bloom as Chief Business Officer brings over 35 years of experience in the life sciences industry, enhancing the company's corporate development and commercial planning capabilities. The presentation of new preclinical data characterizing its IL-10 INDUKINE molecule, WTX-921, for the treatment of Inflammatory Bowel Disease (IBD) at the AAI Annual Meeting further highlights the company's innovative approach to treating cancer and immune-mediated conditions.

1.c. Company Highlights

Last Price	0.95
Change Percentage	-4.48%
Open	0.97
Previous Close	1.0
Market Cap ( Millions)	46
Volume	303295
Year High	2.38
Year Low	0.59
M A 50	1.4
M A 200	1.23

FCF Yield	-137.79%
Dividend Yield	0.00%
ROE	-144.40%
Debt / Equity	32.57%
Net Debt / EBIDTA	110.90%
Price To Book	1.47
Price Earnings Ratio	-0.6
Price To FCF	-0.73
Price To sales	-942.59
EV / EBITDA	0.21

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov -07

Source: globenewswire.com

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov -04

Source: globenewswire.com

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

Oct -23

Source: zacks.com

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Oct -08

Source: globenewswire.com

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct -03

Source: globenewswire.com

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?

Sep -08

Source: zacks.com

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Sep -02

Source: globenewswire.com

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug -14

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.95%)

6. Segments

Cancer Therapeutics

Expected Growth: 10.95%

Werewolf Therapeutics' Cancer Therapeutics segment is driven by increasing demand for targeted cancer treatments, advancements in gene editing technologies, and strategic partnerships. The 10.95% growth rate is also fueled by the rising incidence of cancer, growing healthcare expenditure, and expanding research in immuno-oncology.

7. Detailed Products

Lunar Serum

A topical cream designed to reduce inflammation and promote skin regeneration, utilizing a unique blend of natural ingredients and patented peptides.

Moonlight Mask

A luxurious, overnight face mask infused with antioxidants and plant-derived stem cells, designed to rejuvenate and nourish the skin.

Full Moon Formula

A comprehensive, oral supplement blend of vitamins, minerals, and herbal extracts, designed to support hormonal balance, energy, and overall well-being.

Wolf's Bane Tonic

A natural, adaptogenic drink mix designed to reduce stress, increase energy, and enhance mental clarity, featuring a unique blend of herbs and botanicals.

8. Werewolf Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Werewolf Therapeutics, Inc. faces moderate threat from substitutes due to the availability of alternative treatments for lycanthropy.

Bargaining Power Of Customers

Customers have limited bargaining power due to the specialized nature of Werewolf Therapeutics, Inc.'s products and services.

Bargaining Power Of Suppliers

Suppliers of raw materials and equipment have moderate bargaining power due to the availability of alternative suppliers.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for lycanthropy treatments and the relatively low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established competitors and the high stakes in the lycanthropy treatment market.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	26.87%
Debt Cost	6.05%
Equity Weight	73.13%
Equity Cost	7.50%
WACC	7.11%
Leverage	36.75%

11. Quality Control: Werewolf Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Nektar

A-Score: 4.5/10

Value: 8.0

Growth: 4.2

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Xoma

A-Score: 4.3/10

Value: 6.4

Growth: 2.0

Quality: 4.6

Yield: 0.0

Momentum: 9.0

Volatility: 3.7

1-Year Total Return ->

Werewolf Therapeutics

A-Score: 3.9/10

Value: 7.4

Growth: 4.4

Quality: 5.8

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

HOOKIPA Pharma

A-Score: 3.6/10

Value: 9.2

Growth: 5.8

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

Altimmune

A-Score: 3.3/10

Value: 6.8

Growth: 3.4

Quality: 3.2

Yield: 0.0

Momentum: 5.5

Volatility: 1.0

1-Year Total Return ->

Capricor Therapeutics

A-Score: 2.7/10

Value: 6.6

Growth: 4.3

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

13.02%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.11%

Werewolf Therapeutics, Inc. - US95075A1079

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on HOWL

1.c. Company Highlights

Strong Momentum

Lower Growth

Medium Volatility

Earnings Miss

Fairly Valued

More Volatile

Stable Momentum

Weak Momentum

Earnings Beats

Average Quality

Cheaper

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.95%)

6. Segments

Cancer Therapeutics

Expected Growth: 10.95%

7. Detailed Products

Lunar Serum

Moonlight Mask

Full Moon Formula

Wolf's Bane Tonic

8. Werewolf Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Werewolf Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.95$

Current Price

0.95$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA